ARTL News

Latest breaking news and updates for ARTL stock.

Track all markets on TradingView

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathw...

How does the $4.40 per share pricing, including the warrant terms and underwriting discounts, compare to ARTL’s recent trading range and to similar financing deals in the biotech sector? What are the intended uses of the approximately $3 million net proceeds and how will they support Artelo Biosciences’ near‑term clinical and commercial milestones? How will the issuance of 640,924 new shares and the accompanying pre‑funded warrants dilute existing shareholders and affect ARTL's earnings per share?
Offering
1 day ago
Read more globenewswire

Artelo Biosciences Announces Proposed Underwritten Public Offering

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathw...

What is the intended use of proceeds, and how does this capital raise position Artelo Biosciences relative to its pipeline milestones and peer financing activities? What pricing range and underwriting terms are expected, and how might they influence the stock's immediate trading range? How will the dilution from the underwritten offering affect ARTL's earnings per share and valuation multiples?
Capital raise
2 days ago
Read more globenewswire

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathw...

How does ART27.13's market opportunity and competitive landscape compare to other pipeline assets in the cancer anorexia‑cachexia space? What are the potential near‑term price catalysts from the upcoming full Phase 2 data release and possible partnership announcements? How likely is Artelo Biosciences to secure a development partner for ART27.13 and what terms might be involved?
Clinical trials
2 days ago
Read more globenewswire

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

(NASDAQ:ARTL) Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS

How does ART27.13’s efficacy and safety profile compare with competing CACS therapies, and what is the potential market size and reimbursement outlook? What is the expected timeline and probability of securing partnership or licensing agreements with interested pharmaceutical companies? How will the positive interim Phase 2 results for ART27.13 influence ARTL’s short‑term stock price and valuation?
Clinical trials
2 days ago
Read more globenewswire

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions

What are the potential revenue implications if ART26.12 gains regulatory approval, including projected market size for persistent pain treatments and possible partnership or licensing opportunities? What is the timeline for advancing ART26.12 into later‑stage clinical trials and potential FDA submission, and how does that compare to peer companies developing non‑opioid pain therapies? How will the new fed vs. fasted dosing data for ART26.12 affect market perception and short‑term stock volatility?
Clinical trials
11 days ago
Read more globenewswire